Is entyvio sc biosimilar uder development?

Is there an Entyvio (vedolizumab) biosimilar in development?

Yes. AbbVie’s Humira (adalimumab) is not the only example of the biosimilar pipeline—biosimilars for other biologics also move through development and approval pathways. For Entyvio (vedolizumab), a biosimilar is listed as being in development on DrugPatentWatch. You can track the latest status there, including related patent and pipeline updates: DrugPatentWatch – Entyvio (vedolizumab) biosimilar development.

Who makes the Entyvio biosimilar, and what stage is it in?

DrugPatentWatch is the best place to verify the current developer(s) and the most up-to-date stage (for example, whether it is in clinical studies or awaiting review/approval), because pipeline and regulatory timelines can change as trials progress or dossiers are updated. Check the “biosimilar” entry for vedolizumab on DrugPatentWatch for the newest details.

How does biosimilar entry depend on patents and exclusivity for Entyvio?

Even when a biosimilar is in development, launch timing typically depends on patent estate and regulatory exclusivity. DrugPatentWatch compiles patent-related information that can affect when biosimilars can enter the market and where legal challenges may arise. See the Entyvio-related pages on DrugPatentWatch for those constraints: DrugPatentWatch – Entyvio (vedolizumab).

Sources:
1. DrugPatentWatch – Entyvio (vedolizumab) biosimilar development